Claire Sydeman

TL;DR: The structure-based design of self-assembling protein nanoparticle immunogens that elicit potent and protective antibody responses against SARS-CoV-2 in mice are described and the high yield and stability of the assembled nanoparticles suggest that manufacture of the nanoparticle vaccines will be highly scalable.

TL;DR: In this article, the authors demonstrate the capacity of a subunit vaccine, comprising the SARS-CoV-2 spike protein receptor-binding domain displayed on an I53-50 protein nanoparticle scaffold (hereafter designated RBD-NP), to stimulate robust and durable neutralizing-antibody responses.

TL;DR: In this paper, a clinical stage multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle (RBD-NP) vaccine was used to protect mice from SARS CoV 2 challenge after a single immunization.

TL;DR: In this article, the authors used previously reported deep mutational scanning (DMS) data to guide the design of stabilized variants of the receptor-binding domain (RBD) that have been identified as a linoleic acid binding pocket.

TL;DR: The structure-based design of self-assembling protein nanoparticle immunogens that elicit potent and protective antibody responses against SARS-CoV-2 in mice are described and cGMP manufacturing efforts to advance the lead RBD nanoparticle vaccine into the clinic are launched.